Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Ye Wei

Citation

Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421

Authors

Y. Wei1, Y. Chen2, W. Chang1, J. Xu3

Author affiliations

  • 1 Colorectal Cancer Center; Department Of General Surgery, Zhongshan Hospital, Fudan University, 200010 - shanghai/CN
  • 2 Colorectal Cancer Center; Department Of General Surgery, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 3 General Surgery, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 95P

Background

The type of liver resection (anatomical resection, AR or nonanatomical resection, NAR) for colorectal liver metastases (CRLM) is subject to debate. The debate may persist because some certain prognostic implications, associated with worse biological behavior of tumors, have been overlooked. The aim of this study was to explore the characteristics of patients who would benefit more from the performance of AR.

Methods

475 patients who underwent hepatic resection of CRLM were included and stratified by KRAS/NRAS/BRAF mutational status. The Kaplan-Meier method was applied in relapse-free survival (RFS), and the Cox proportional hazards model was used to identify independent predictors of prognosis in multivariable analysis.

Results

Among all 475 patients, 154 (32.4%) underwent AR and 321 (67.6%) underwent NAR. 1-, 2-, and 3-year RFS for the entire cohort were 63.0%, 40.6%, and 31.2% respectively. In the cohort of patients with KRAS/NRAS/BRAF mutated tumors, patients who underwent AR had a markedly improved median RFS compared with patients who underwent NAR (24.1 VS. 12.9 months, P = 0.005). Upon the multivariable analyses, the performance of AR (hazard ratios=0.562; 95% CI 0.370-0.854, P = 0.007) remained prognostic independently for a superior RFS. In contrast, in the cohort of patients with KRAS/NRAS/BRAF wild-type tumors, patients who underwent AR had a comparable median RFS compared with those who underwent NAR (24.9 VS. 20.3 months, P = 0.901).

Conclusions

Patients with KRAS/NRAS/BRAF mutated tumors may benefit more from the performance of AR than from the performance of NAR.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Zhongshan Hospital.

Funding

The National Natural Science Foundation of China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.